Inferra AI / Company / SUPN
Supernus Pharmaceuticals, Inc.
SUPN · Health Care
Last earnings Oct 29, 2026
Key results
Combined revenuequarter
52%
htm EX-99.1 Document Exhibit 99.1 Supernus Announces Third Quarter 2025 Financial Results Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Total revenuequarter
$192.1 million
Total revenues were $192.1 million in the third quarter of 2025, a 9% increase compared to the same period in 2024.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Collaboration revenuequarter
$20.2 million
Collaboration revenue from ZURZUVAE was $20.2 million in the third quarter of 2025, representing approximately two months of collaboration revenue reported by Supernus since the closing of the Sage acquisition on July 31, 2025.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
AI analysis
Q3 2025 · reported Nov 4, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q3 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Combined revenue | 52% | — | — |
| Total revenue | $192.1 million | $165.5 million | — |
| Collaboration revenue | $20.2 million | — | — |
Guidance · company-stated
Direction: Raised
“Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong performance in the first nine months of 2025.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Immediately prior to the Effective Time, stockholders of Indivior will receive a one-time special cash dividend of $ 1.0 billion.
Event summary
Supernus Announces Third Quarter 2025 Financial Results Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue — Raised (“Increasing”)
“Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong performance in the first nine months of 2025.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Immediately prior to the Effective Time, stockholders of Indivior will receive a one-time special cash dividend of $ 1.0 billion.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
Indivior has secured a debt commitment of $ 650 million through a term loan facility, and the remaining portion will be funded by existing cash of the then-combined company.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
The amounts recognized reflect the present value of remaining lease payments, discounted at the Company's incremental borrowing rate.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
government agency and municipal debt securities Amortized cost $ 183,862 $ 180,215 Gross unrealized gains 34 Gross unrealized losses ( 287 ) ( 27 ) Total fair value $ 183,575 $ 180,222 As of September 30, 2026, all of the Company's unrestricted available-for-sale marketable securities have contractual maturities of one year or less.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
S government agency securities Other noncurrent assets Marketable securities - restricted (SERP) 767 32 735 Restricted cash 1,450 1,450 Total assets at fair value $ 361,676 $ 177,366 $ 184,310 $ Liabilities: Contingent consideration $ 206 $ $ $ 206 Total liabilities at fair value $ 206 $ $ $ 206 Fair Value Measurements as of December 31, 2025 Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents Cash $ 56,371 $ 56,371 $ $ Money market funds 72,077 72,077 Marketable securities Corporate debt securities 164,519 164,519 Municipal debt securities 14,716 14,716 U.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
government agency debt securities 987 987 Other noncurrent assets Marketable securities - restricted (SERP) 705 27 678 Restricted Cash 1,450 1,450 $ Total assets at fair value $ 310,825 $ 129,925 $ 180,900 $ Liabilities: Contingent consideration $ 31,258 $ $ $ 31,258 Total liabilities at fair value $ 31,258 $ $ $ 31,258 Other Financial Instruments The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses approximate fair value due to their short-term maturities.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
Strategy & priorities
(Nasdaq SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2025 and associated Company developments.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
As a result of this supply imbalance, the Company is prioritizing care for patients currently on ONAPGO.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
(the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies ) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
Risks & headwinds
These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Legal Proceedings 47 Item 1A.
SEC original ↗Supernus Pharmaceuticals, Inc. — 10-Q Quarterly report10-QOct 29, 2026
What changed vs prior quarter
Guidance direction — prior quarter: Raised; this quarter: Raised
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Total revenue — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Supernus Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Nov 4, 2025
Earnings deck slides
0 decks with slide viewSupernus Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
39 documents- Q3 2026
- 8-KSUPN
- 10-QSUPN
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- EX-99SUPN
- 8-KSUPN
- Q2 2026
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- 10-QSUPN
- 8-KSUPN
- EX-99SUPN
- Q1 2026
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- 10-QSUPN
- 8-KSUPN
- EX-99SUPN
- 8-KSUPN
- Q4 2025
- 10-KSUPN
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- EX-99SUPN
- 8-KSUPN
- Q3 2025
- 10-QSUPN
- 8-KSUPN
- 8-KSUPN
- EX-99SUPN
- 8-K/ASUPN
- Q2 2025
- 8-KSUPN
- 10-QSUPN
- 8-KSUPN
- 8-KSUPN
- 8-KSUPN
- EX-99SUPN
- Q1 2025
- 8-KSUPN
Earnings releases
11 documentsPresentations
1 document- Q2 2026
- SUPNDeck
Transcripts
0 documentsNo transcripts for Supernus Pharmaceuticals, Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Supernus Pharmaceuticals, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
Harmony Biosciences Holdings, Inc. (HRMY)
“ previously served as Chairman of the Board of Sage Therapeutics until its acquisition by Supernus Pharmaceuticals in July 2025, and currently holds Board positions with both Precision Biosciences… …long-term value creation for our shareholders. I wa”
See also the earnings calendar for every tracked company’s next earnings date.